References
- Drummond M, Ruten F, Brena A, Gouveia Pinto C, Horisberger B, Jönsson B, et al. Economic evaluation of pharmaceuticals. A European perspective. Pharmaco Economics 1993; 4: 173–86
- Roos K, Holm S E, Ekedahl C. Treatment failure in acute streptococcal tonsillitis in children over the age of 10 and in adults. Clinical and therapeutical aspects. Scand J Infect Dis 1985; 17: 357–65
- Strömberg A, Schwan A, Cars O. Five versus ten days treatment of Group A streptococcal pharyngotonsillitis: a randomized controlled clinical trial with phenoxymethylpenicillin and cefadroxil. Scand J Infect Dis 1988; 20: 37–46
- Claesson R, Persson U, Roos K, Ödegaard K. The economic cost of a tonsillitis episode. Lund 1993; 9, IHE Working paper
- Roos K. Acute streptococcal tonsillitis in children over the age of 10 and in adults with special reference to treatment failure. University of Göteborg. 1985; 5, Ph.D. Thesis
- Pichichero M. The rising incidence of penicillin treatment failures in group A streptococcal tonsil-lopharyngitis: an emerging role for the cephalosporins. Ped Infect Dis J 1991; 10: 50–5
- Holm S E, Roos K, Strömberg A. A randomized study of treatment of streptococcal pharyngotonsillitis with cefadroxil or phenoxymethylpenicillin (penicillin V). Ped Infect Dis J 1991; 10: 68–71
- Roos K, Holm S E, Grahn E, Lind L. Alpha-streptococci as supplementory treatment of recurrent streptococcal tonsillitis: a randomized placebo-controlled study. Scand J Infect Dis 1993; 25: 31–5
- Neu H. The crisis in antibiotic resistance. Science 1992; 257: 1064–73